



Company Overview

Iterum Therapeutics plc is focused on delivering differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum is advancing the development of its first compound, sulopenem, a novel penem anti-infective compound, with an oral formulation and IV formulation. Sulopenem has demonstrated potent in vitro activity against a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics. Iterum has received approval of its NDA for ORLYNVAH™ (oral sulopenem) for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms *Escherichia coli*, *Klebsiella pneumoniae*, or *Proteus mirabilis* in adult women with limited or no alternative oral antibacterial treatment options by the U.S. Food and Drug Administration.

[Sign up here](#) to receive notices about press releases and SEC filings.

Iterum Therapeutics Provides Business Update

Feb 13 2026, 8:00 AM EST

Iterum Therapeutics Provides Business Update

Dec 23 2025, 8:00 AM EST

Iterum Therapeutics Provides Business Update

Dec 17 2025, 8:00 AM EST

Stock Overview

| | |
|------------|-------------------|
| Symbol | ITRM |
| Exchange | Nasdaq |
| Market Cap | 9.3m |
| Last Price | \$0.176 |
| 52-Week | \$0.1357 - \$1.42 |

03/26/2026 08:00 PM EDT

Investor Relations

ir@iterumtx.com

Management Team

Corey N. Fishman

Chief Executive Officer

Judith M. Matthews

Chief Financial Officer

Christine R. Coyne, MBA

Chief Commercial Officer

Tom Loughman, PhD

Senior Vice President, Technical Operations

Steven I. Aronin, MD

Senior Vice President and Head of Clinical Development

Iterum Therapeutics plc

200 S Wacker Drive
Suite 3100
Chicago, IL 60606
USA

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.